Gallbladder cancer other imaging findings: Difference between revisions
Jump to navigation
Jump to search
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Gallbladder cancer}} | {{Gallbladder cancer}} | ||
{{CMG}}{{AE}}{{ | {{CMG}} ; {{AE}} {{VKG}} | ||
==Overview== | ==Overview== | ||
PET scan may be helpful in the diagnosis of gallbladder | [[FDG]]-[[PET]] scan may be helpful in the [[diagnosis]] of the [[gallbladder]]. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
*Given the rate of high [[incidence]] of [[Metastasis|metastases]] in [[gallbladder cancer]], FDG([[fluorodeoxyglucose]]), [[Positron emission tomography|PET]]([[positron emission tomography]]) [[scan]] is particularly useful in identifying [[Metastasis|metastases]].<ref name="CorveraBlumgart2008">{{cite journal|last1=Corvera|first1=Carlos U.|last2=Blumgart|first2=Leslie H.|last3=Akhurst|first3=Timothy|last4=DeMatteo|first4=Ronald P.|last5=D’Angelica|first5=Michael|last6=Fong|first6=Yuman|last7=Jarnagin|first7=William Robert|title=18F-fluorodeoxyglucose Positron Emission Tomography Influences Management Decisions in Patients with Biliary Cancer|journal=Journal of the American College of Surgeons|volume=206|issue=1|year=2008|pages=57–65|issn=10727515|doi=10.1016/j.jamcollsurg.2007.07.002}}</ref><ref name="pmid17385310">{{cite journal |vauthors=Oe A, Kawabe J, Torii K, Kawamura E, Higashiyama S, Kotani J, Hayashi T, Kurooka H, Tsumoto C, Kubo S, Shiomi S |title=Distinguishing benign from malignant gallbladder wall thickening using FDG-PET |journal=Ann Nucl Med |volume=20 |issue=10 |pages=699–703 |year=2006 |pmid=17385310 |doi= |url=}}</ref><ref name="pmid14746840">{{cite journal |vauthors=Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D |title=Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma |journal=J. Gastrointest. Surg. |volume=8 |issue=1 |pages=90–7 |year=2004 |pmid=14746840 |doi= |url=}}</ref><ref name="pmid20495711">{{cite journal |vauthors=Butte JM, Redondo F, Waugh E, Meneses M, Pruzzo R, Parada H, Amaral H, De La Fuente HA |title=The role of PET-CT in patients with incidental gallbladder cancer |journal=HPB (Oxford) |volume=11 |issue=7 |pages=585–91 |year=2009 |pmid=20495711 |pmc=2785954 |doi=10.1111/j.1477-2574.2009.00104.x |url=}}</ref><ref name="pmid18155569">{{cite journal |vauthors=Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, Jarnagin WR |title=18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer |journal=J. Am. Coll. Surg. |volume=206 |issue=1 |pages=57–65 |year=2008 |pmid=18155569 |doi=10.1016/j.jamcollsurg.2007.07.002 |url=}}</ref> | |||
===PET=== | *<nowiki/>[[Positron emission tomography|PET]] scan is useful in diagnosing [[Abnormal|abnormal]]<nowiki/> lesions and detecting [[residual]] disease after [[cholecystectomy]]. | ||
*PET scan has the ability to detect [[occult]]<nowiki/> [[metastasis]] in patients with potentially resectable [[Tumor|tumors]] and changes the management in almost 25% of the patients. | |||
*[[Percutaneous]] transhepatic cholecystoscopy and [[Percutaneous]] transhepatic [[fine needle aspiration]] are helpful in the evaluation of [[gallbladder]] [[Polyp|polyps]]. | |||
==References== | ==References== | ||
| Line 20: | Line 21: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
[[Category:Hepatology]] | |||
Latest revision as of 15:20, 10 January 2019
|
Gallbladder cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gallbladder cancer other imaging findings On the Web |
|
American Roentgen Ray Society Images of Gallbladder cancer other imaging findings |
|
Risk calculators and risk factors for Gallbladder cancer other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
FDG-PET scan may be helpful in the diagnosis of the gallbladder.
Other Imaging Findings
- Given the rate of high incidence of metastases in gallbladder cancer, FDG(fluorodeoxyglucose), PET(positron emission tomography) scan is particularly useful in identifying metastases.[1][2][3][4][5]
- PET scan is useful in diagnosing abnormal lesions and detecting residual disease after cholecystectomy.
- PET scan has the ability to detect occult metastasis in patients with potentially resectable tumors and changes the management in almost 25% of the patients.
- Percutaneous transhepatic cholecystoscopy and Percutaneous transhepatic fine needle aspiration are helpful in the evaluation of gallbladder polyps.
References
- ↑ Corvera, Carlos U.; Blumgart, Leslie H.; Akhurst, Timothy; DeMatteo, Ronald P.; D’Angelica, Michael; Fong, Yuman; Jarnagin, William Robert (2008). "18F-fluorodeoxyglucose Positron Emission Tomography Influences Management Decisions in Patients with Biliary Cancer". Journal of the American College of Surgeons. 206 (1): 57–65. doi:10.1016/j.jamcollsurg.2007.07.002. ISSN 1072-7515.
- ↑ Oe A, Kawabe J, Torii K, Kawamura E, Higashiyama S, Kotani J, Hayashi T, Kurooka H, Tsumoto C, Kubo S, Shiomi S (2006). "Distinguishing benign from malignant gallbladder wall thickening using FDG-PET". Ann Nucl Med. 20 (10): 699–703. PMID 17385310.
- ↑ Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D (2004). "Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma". J. Gastrointest. Surg. 8 (1): 90–7. PMID 14746840.
- ↑ Butte JM, Redondo F, Waugh E, Meneses M, Pruzzo R, Parada H, Amaral H, De La Fuente HA (2009). "The role of PET-CT in patients with incidental gallbladder cancer". HPB (Oxford). 11 (7): 585–91. doi:10.1111/j.1477-2574.2009.00104.x. PMC 2785954. PMID 20495711.
- ↑ Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, Jarnagin WR (2008). "18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer". J. Am. Coll. Surg. 206 (1): 57–65. doi:10.1016/j.jamcollsurg.2007.07.002. PMID 18155569.